GlassScriptPhysician profile
Noor M Merchant
NPI 1346227352
$27,102.95
in general payments reported to CMS, 2019-2025
83 companies · $3,999 in 2025
The $3,999 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,327 · 2020: $2,988 · 2021: $4,487 · 2022: $4,134 · 2023: $3,667 · 2024: $4,501 · 2025: $3,999.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,014.23 |
| Education | $153.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,840.95 | 2019-2025 | |
| Pfizer INC. | $1,921.50 | 2019-2025 | |
| Janssen Biotech, INC. | $1,773.37 | 2019-2025 | Darzalex, Tecvayli, Rybrevant |
| Merck Sharp & Dohme LLC | $1,631.07 | 2019-2025 | Keytruda, Lynparza, Welireg |
| E.R. Squibb & Sons, L.L.C. | $1,540.87 | 2019-2025 | Opdivo, Opdualag |
| Astrazeneca Pharmaceuticals LP | $1,363.12 | 2019-2025 | Enhertu, Lynparza, Imfinzi |
| Celgene Corporation | $983.73 | 2019-2025 | Pomalyst, Reblozyl, Opdivo |
| Glaxosmithkline, LLC. | $978.30 | 2020-2025 | Ojjaara, Zejula, Jemperli |
| Astellas Pharma US INC | $789.49 | 2019-2025 | Xtandi, Vyloy, Xospata |
| Pharmacyclics LLC, An Abbvie Company | $732.97 | 2019-2023 | Imbruvica, Epkinly |
| Seagen INC. | $724.65 | 2019-2023 | Tivdak, Adcetris, Padcev |
| Incyte Corporation | $694.01 | 2019-2025 | Jakafi, Monjuvi, Zynyz |
| Genzyme Corporation | $690.52 | 2019-2025 | |
| Abbvie INC. | $665.92 | 2020-2025 | |
| Amgen INC. | $609.38 | 2019-2023 | Kyprolis, Lumakras |
Show all 83 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Noor Merchant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.